1-12 of 12
Yuping Zhong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Clinical Outcomes of Daratumumab-Based Regimens in Chinese Patients with Multiple Myeloma By Cytogenetic Risk: A Subgroup Analysis of the MMY4032 Study

Luqun Wang, Wei Yang, Ting Niu, Yafei Wang, Rong Fu, Yuping Zhong, Kaiyang Ding, Kai Sun, Baijun Fang, Hong Liu, Wenbin Qian, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Canchan Cui, Jin Lu
Journal: Blood
Blood (2024) 144 (Supplement 1): 7874.
https://doi.org/10.1182/blood-2024-201134
Published: 2024
Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Jin Lu, Liangquan Geng, Lijuan Chen, Peng Liu, Yuping Zhong, Zhuogang Liu, Zhongjun Xia, Jianqing Mi, Chunrui Li, Xi Zhang, Yanjuan He, Yongqiang Wei, Baijun Fang, Fei Li, Zhen Cai, Yafei Wang, Dongping Huang, Hong Liu, Ming Hou, Rong Fu, Xin Du, Xiaosheng Fang, Qingshu Zeng, Wen Gao, Wei Wang, Chunkang Chang, Guifang Ouyang, Jing Liu, Jianyu Weng, Xiaobing Huang, Yang Yu, Zhi Guo, Jun Zhao, Jian Hou
Journal: Blood
Blood (2024) 144 (Supplement 1): 4748.
https://doi.org/10.1182/blood-2024-202893
Published: 2024
Journal Articles

An Uniquely Designed Asymmetric Bispecific Antibody Against GPRC5D and CD3 (LBL-034) in Patients with Relapsed/Refractory Multiple Myeloma: A Phase I/II, First in Human, Open-Label, Multicenter, Dose Escalation/Expansion Study

Ling Qin, Yuping Zhong, Dongping Huang, Haitang Xie, Xin Du, Aijun Liao, Hongli Zhang, Shengli (Charles) Cai, Jin Lu
Journal: Blood
Blood (2024) 144 (Supplement 1): 4736.
https://doi.org/10.1182/blood-2024-202871
Published: 2024
Journal Articles

Efficacy and Safety Analysis of Carfilzomib-Containing Regimen in the Treatment of Multiple Myeloma：a Multicenter Real-World Study

Na Liu, Luqun WANG, Rentong Liu, Yuping Zhong, Xianqi Feng, Zhongliang Sun, Jie Li, Fanjun Meng, Junjie MA, Changyong Yuan, Hao Li, Ling Wang, Zhilong Xu, Jie Yu, Hao Zhang, Chen Chunyan
Journal: Blood
Blood (2023) 142 (Supplement 1): 6632.
https://doi.org/10.1182/blood-2023-179687
Published: 2023
Journal Articles

Selinexor Combined Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma with Extramedullary Disease(EMD) or High-Risk Cytogenetics

Yuping Zhong, Xiaoxia Chu, Junqing Xu, Xiaoqian Liu, Chenglu Yuan, Xia Zhou, Hongying Wu, Yayun Wang, Shuyuan Yu, Hongyan Zhang, Jay Mei
Journal: Blood
Blood (2023) 142 (Supplement 1): 6620.
https://doi.org/10.1182/blood-2023-172937
Published: 2023
Journal Articles

Real-World Analysis of Treatment Patterns and the Effectiveness and Safety Profile of Daratumumab-Based Regimens in Chinese Patients with Newly Diagnosed or Relapsed/Refractory Multiple Myeloma

Luqun Wang, Wei Yang, Yafei Wang, Ting Niu, Rong Fu, Yuping Zhong, Wenbin Qian, Kaiyang Ding, Kai Sun, Hong Liu, Baijun Fang, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Canchan Cui, Jin Lu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6635.
https://doi.org/10.1182/blood-2023-180948
Published: 2023
Journal Articles

Interim Report of Bendamustine Plus Rituximab As First-Line Induction Therapy with or without Lenalidomide Maintenance Therapy in Chinese Patients with Indolent Non-Hodgkin's Lymphoma or Elderly Mantle Cell Lymphoma: Data from a Multi-Center Prospective Trial

Hui Wang, Qiang He, Rongrong Zhao, Linna Xie, Ji Ma, Cong Liu, Ke Lu, Haichen Wei, Dan Liu, Lijie Xing, Xiuzhi Deng, Zhongliang Sun, Xiaoxia Chu, Na Gao, Yuping Zhong, Yanhua Sun, Haiyan Zhang, Hao Zhang, Wenwei Xu, Zengjun Li
Journal: Blood
Blood (2022) 140 (Supplement 1): 11962–11963.
https://doi.org/10.1182/blood-2022-162507
Published: 2022
Journal Articles

Which Should be Pursued, Cumulative Dose or Dose Intensity: A Real-World Effectiveness Analysis of Bortezomib-Based First Line Treatment for Untreated Multiple Myeloma Patients

Shenmiao Yang, MD, Aijun Liu, MD, Yuping Zhong, MD, Xiaojun Huang, MDPhD, Wenming Chen, MD, Jin Lu
Journal: Blood
Blood (2015) 126 (23): 4247.
https://doi.org/10.1182/blood.V126.23.4247.4247
Published: 2015
Journal Articles

Detection of Circulating Plasma Cells in Multiple Myeloma with Extramedullary Plasmacytoma

Jing Wang, Shuang Geng, Yuping Zhong, MD, Mingyi Chen, MD PhD, Wenming Wang, Yuhong Pang, PhD, Jiajia Zhang, Yuanyuan Liu, Yanyi Huang, PhD, Hongmei Jing, MD
Journal: Blood
Blood (2015) 126 (23): 5328.
https://doi.org/10.1182/blood.V126.23.5328.5328
Published: 2015
Journal Articles

Regulation Of DKK-1 Expression By p38 MAPK Signaling Via CREB Myeloma Cells

Jing Yang, PhD, Yuping Zhong, MD, Jin He, Zhiqiang Liu, PhD, Huan Liu, Pei Lin, MD, Robert Z. Orlowski, M.D., Ph.D., Larry W. Kwak, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1917.
https://doi.org/10.1182/blood.V122.21.1917.1917
Published: 2013
Journal Articles

Ex Vivo Expansion and Long-Term Hematopoietic Reconstitution Ability of Sorted CD34+CD59+ Cells from Patients with Paroxysmal Nocturnal Hemoglobinuria.

Juan Xiao, MD, PhD, Bing Han, MD, PhD, Wanling Sun, MD, PhD, Yuping Zhong, MD, PhD, Yongji Wu, MD
Journal: Blood
Blood (2008) 112 (11): 2324.
https://doi.org/10.1182/blood.V112.11.2324.2324
Published: 2008
Journal Articles

Bortezomib Plus Thalidomide Treatment of Newly Diagnosed Patients with Multiple Myeloma - Efficacy and Neurotoxicity: Results of a Multicenter Study.

Shilun Chen, MD, Bin Jiang, MD, Lugui Qiu, MD, Li Yu, MD, Yuping Zhong, MD, Wen Gao, MD
Journal: Blood
Blood (2007) 110 (11): 3600.
https://doi.org/10.1182/blood.V110.11.3600.3600
Published: 2007